MedTrace Logo

Phase II Study of TAEST16001 in Soft Tissue Sarcoma

NCT05549921 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-12-27

No results posted yet for this study

Summary

The main purpose of this trial is to evaluate the efficacy and safety of TAEST16001 cells in the treatment of advanced soft tissue sarcoma patients with HLA-A\*02:01 tissue genotype and positive tumor antigen NY-ESO-1 expression.

Conditions

  • Soft Tissue Sarcoma

Interventions

BIOLOGICAL

NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)

NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)

Sponsors & Collaborators

  • Guangdong Xiangxue Precision Medical Technology Co., Ltd.

    collaborator INDUSTRY

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Xing Zhang, PhD, MD · Sun Yat-sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-08
Primary Completion
2024-09-01
Completion
2024-09-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05549921 on ClinicalTrials.gov